Cellular or tissue FFPE available

Indication of treatment with pembrolizumab + first line chemotherapy in multidisciplinary consultation meeting

No mutation of the EGFR gene, no rearrangement of ALK and ROS,

At least one measurable tumor according to RECIST criteria

Tissue or cellular FFPE not available

Systemic anti-neoplastic or immunotherapy previously received except neoadjuvant or adjuvant treatment completed 6 months or more

Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer